Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritlecitinib in adults with chronic spontaneous urticaria
2025-522642-44-00Phase 2Authorised
- Sponsor
- Pfizer
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of ritlecitinib tosilate in chronic idiopathic urticaria (CIU) (3 arms), sponsored by Pfizer. Primary endpoints: Change from baseline in UAS7 at Week 12 and Incidence of TEAEs, SAEs, and AEs leading to discontinuation. Planned start Mar 2026; status: authorised.
02
Drugs
ritlecitinib tosilate
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2025-522642-44-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522642-44-00.